Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention: A Nationwide Cohort Study.

JACC. Asia·2026
Same author

Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences.

European heart journal·2026
Same author

2025 Acute Coronary Syndrome Guideline: Missing the Boat on <i>CYP2C19</i> Genotyping.

Journal of the American Heart Association·2026
Same author

Guided de-escalation of antiplatelet treatment in patients at high atherothrombotic risk presenting with acute coronary syndrome: a post hoc analysis of the TROPICAL-ACS trial.

European heart journal. Acute cardiovascular care·2025
Same author

Dual antiplatelet therapy modulation strategies beyond standard of care: a promising path towards individualized antiplatelet treatment.

European heart journal·2025
Same author

Advanced Subclinical Atherosclerosis and Low-Dose Aspirin: Guideline-Based Extension Into Asymptomatic Chronic Coronary Syndromes.

JACC. Advances·2025
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelet function testing and risk of bleeding complications.

José Luis Ferreiro1, Dirk Sibbing, Dominick J Angiolillo

  • 1University of Florida College of Medicine, Jacksonville, FL 32209, USA.

Thrombosis and Haemostasis
|March 31, 2010
PubMed
Summary
This summary is machine-generated.

Platelet function testing helps balance antiplatelet therapy's benefits against bleeding risks in coronary artery disease patients. It identifies individuals prone to ischemic or bleeding complications, guiding personalized treatment for better outcomes.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Related Experiment Videos

Last Updated: Jun 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro
10:25

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Antiplatelet therapy is crucial for preventing atherothrombotic events in coronary artery disease (CAD), especially post-revascularization.
  • Balancing antithrombotic efficacy against bleeding risk is critical for optimal patient outcomes.
  • Individual responses to antiplatelet drugs vary, influencing thrombotic and bleeding event rates.

Purpose of the Study:

  • To review evidence linking platelet function testing (PFT) to adverse clinical outcomes, particularly bleeding.
  • To explore the potential applications of PFT in guiding therapy with new antithrombotic agents.

Main Methods:

  • Review of existing literature and clinical studies.
  • Analysis of data associating PFT results with ischemic and bleeding complications.
  • Discussion of the clinical utility of PFT in managing antiplatelet therapy.

Main Results:

  • Platelet function assays can identify patients at increased risk for both thrombotic and bleeding events.
  • Variability in platelet inhibition levels correlates with differing clinical outcomes.
  • PFT may help personalize antiplatelet treatment strategies.

Conclusions:

  • Platelet function testing is a valuable tool for assessing individual response to antiplatelet therapy.
  • PFT can aid in optimizing treatment to minimize bleeding and thrombotic risks in CAD patients.
  • The role of PFT is expected to grow with the advent of novel antithrombotic agents.